Peritoneal carcinomatosis as a pathway of metastatic dissemination in a patient with gastroesophageal junction cancer: case report and review




EC, Peritoneal carcinomatosis, Surgery, Surgical oncology


The oesophageal adenocarcinoma is an increasing pathology in the last decade, predominantly in the western population. A characteristic of esophageal cancer (EC) and esophageal-gastric junction cancer (EGJC) is the high percent of metastatic disease at the time of diagnosis one of the main causes of death in these patients. The present case is about a 78-year-old man, diagnosed with Barrett's esophagus with high-grade dysplasia and stenosis of distal third of esophagus, during surgery we found peritoneal carcinomatosis with implants in gut and no resectably disease.


Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, et al. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014;86:336-9.

Robb WB, Messager M, Dahan L, Mornex F, Maillard E, D’Journo XB, et al. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone. Br J Surg. 2016;103:117-25.

Wu SG, Zhang WW, Sun JY, Li FY, Lin Q, He ZY. Patterns of Distant Metastasis Between Histological Types in Esophageal Cancer. Frontiers in Oncol. 2018;8.

Verstegen MHP, Harker M, van de Water C, van Dieren J, Hugen N, Nagtegaal ID, et al. Metastatic pattern in esophageal and gastric cancer: Influenced by site and histology. World J Gastroenterol. 2020;26(39):6037-46.

Waddell T. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncol. 2013;14:481-9.

Lordick F. Capecitabine and cisplatin with

or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncol. 2013;14:490-9.

Shah MA. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2‐negative, MET‐positive gastroesophageal adenocarcinoma: the MET Gastric randomized clinical trial. JAMA Oncol. 2017;3:620-7.

Napier KJ, Scheerer M, Misra S. Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6(5):112-20.

Kong JH, Lee J, Yi CA, Park SH, Park JO, Park YS, et al. Lung metastases in metastatic gastric cancer: pattern of lung metastases and clinical outcome. Gastric Cancer. 2011;15(3):292-8.

Shaheen O, Ghibour A, Alsaid B. Esophageal Cancer Metastases to Unexpected Sites: A Systematic Review. Gastroenterol Res Pract. 2017;1-13.

Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Surg. 2006;95:260-9.

Mostafa E, Ahmed, KB. Impact of diagnostic laparoscopy in the management of gastric cancer in Egyptian patients. The Egyp J Surg. 2019;38(3):394-8.

Steyerberg EW, Neville BA, Kopper LB. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol. 2006;24:4277-84.

Jiang KY, Huang H, Chen WY, Yan HJ, Zhen-Ting W, Xiao-Wen W, et al. Risk factors for LNM: A meta-analysis. World J Gastroenterol. 2021;27(8):737-50.

Allen CJ, Blumenthaler AN, Das P, Minsky BD, Blum M, Roy-Chowdhuri S, et al. Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma. World J Surg Oncol. 2020;18(1):2020.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Esophageal and Esophagogastric Junction Cancers. 2022;5.






Case Reports